400899-99-2

Usage

Uses

Used in Pesticide and Herbicide Production:
Carbamic acid, (trans-4-hydroxycyclohexyl)methyl-, 1,1-dimethylethyl ester is used as an active ingredient in the production of pesticides and herbicides. It acts as an insect repellent, helping to control and prevent infestations in agricultural fields and gardens.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, Carbamic acid, (trans-4-hydroxycyclohexyl)methyl-, 1,1-dimethylethyl ester is used as an intermediate in the synthesis of various drugs. Its unique chemical properties make it a valuable component in the development of new medications and therapies.

Upstream product

• 34619-03-9 tert-butyldicarbonate 
• 22348-44-3 trans-4-Methylamino-cyclohexanol 
• 111300-06-2 trans-tert-butyl 4-hydroxycyclohexylcarbamate 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27489-63-0 trans-4-<(benzyloxycarbonyl)amino>cyclohexanol 

Downstream Products

• 400898-24-0 [4-(4-bromo-butoxy)-cyclohexyl]-methyl-carbamic acid tert-butyl ester 
• 1346763-38-9 trans-4-[{2-[({[4-({[tert-butyl(dimethyl)silyl]oxy}methyl)-2-chloro-5-methoxyphenyl]amino}carbonyl)oxy]ethyl}(methyl)amino]cyclohexylhydroxyl(di-2-thienyl)acetate 
• 1346762-55-7 trans-4-[(9-{[(2R)-2-{[tert-butyl(dimethyl)silyl]oxy}-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethyl]amino}nonyl)(methyl)amino]cyclohexylhydroxy(di-2-thienyl)acetate 
• 1346763-15-2 trans-4-((3-(4-((tert-butyl(dimethyl)silyloxy)methyl)-2-chloro-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)-acetate 
• 1346763-16-3 trans-4-((3-(2-chloro-4-(hydroxymethyl)-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-18-5 trans-4-((3-(2-chloro-4-formyl-5-methoxyphenylamino)-3-oxopropyl)(methyl)amino)cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-32-3 trans-4-[{3-[2-chloro-4-(hydroxymethyl)-5-methoxyphenoxy]propyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-34-5 trans-4-[[3-(2-chloro-4-formyl-5-methoxyphenoxy)propyl](methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346765-37-4 trans-4-[(2-hydroxyethyl)(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-42-5 trans-4-[{2-[({[2-chloro-4-(hydroxymethyl)-5-methoxyphenyl]amino}carbonyl)oxy]ethyl}(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346763-43-6 trans-4-[[2-({[(2-chloro-4-formyl-5-methoxyphenyl)amino]carbonyl}oxy)ethyl](methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346762-52-4 trans-4-(methylamino)cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346762-54-6 trans-4-[(9-bromononyl)(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)acetate 
• 1346762-49-9 trans-4-[(tert-butoxycarbonyl)(methyl)amino]cyclohexyl hydroxy(di-2-thienyl)-acetate 

Relevant academic research and scientific papers

BTK INHIBITOR

Provided are a series of BTK inhibitors, and specifically disclosed are a compound, pharmaceutically acceptable salt thereof, tautomer thereof or prodrug thereof represented by formula (I), (II), (III) or (IV).

New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities

The present invention relates to novel compounds having β2 adrenergic agonist and M3 muscarinic antagonist dual activity, to pharmaceutical compositions containing them, to the process for their preparation and to their use in respiratory therapies.

TRI-SUBSTITUTED PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE10 INHIBITORS

The present invention provides a tri-substituted pyrimidine compound having an excellent PDE10 inhibitory activity. The present invention relates to a tri-substituted pyrimidine compound represented by the following formula [I0] or a pharmaceutically acceptable salt thereof, a method for preparing the same, and use of said compound for PDE10 inhibitor, and a pharmaceutical composition comprising said compounds as an active ingredient: wherein: either one of X1 and X2 is N, and the other of X1 and X2 is CH; A is *-CH═CH—, *-C(Alk)=CH—, *-CH2—CH2— or *-O—CH2— (* is a bond with R1); Alk is a lower alkyl group; Ring B is an optionally substituted nitrogen-containing aliphatic heterocyclic group; R1 is an optionally substituted quinoxalinyl or an optionally substituted quinolyl; Y0 is mono- or di-substituted amino group, or a pharmaceutically acceptable salt thereof.

Oxidosqualene cyclase (OSC) inhibitors for the treatment of dyslipidemia

Novel inhibitors of oxidosqualene cyclase (OSC) for the treatment of dyslipidemia are reported. Starting point for the chemistry program was a set of compounds derived from a fungicide project which, in addition to high affinity for OSC from Candida albicans, also showed high affinity for the human enzyme (hOSC). Here the evaluation process of different scaffolds is outlined for two representative series, the phenyl substituted benzo[d]isothiazoles and the aminocyclohexanes. The most promising compounds derived from the latter series were further profiled in vivo and showed promising properties with respect to modulation of lipid parameters. Schweizerische Chemische Gesellschaft.